Single BNT162b2 vaccine dose produces seroconversion in under 60 s cohort

INTRODUCTION: The coronavirus disease 2019 (COVID-19) pandemic has led to worldwide vaccination development efforts. In December 2020 the Pfizer BNT162b2 vaccine was approved in the United States. This study describes the first BNT162b2 vaccine dose effect on a large cohort. METHODS: This retrospect...

Descripción completa

Detalles Bibliográficos
Autores principales: Shachor-Meyouhas, Yael, Hussein, Khetam, Szwarcwort-Cohen, Moran, Weissman, Avi, Mekel, Michal, Dabaja-Younis, Halima, Hyams, Gila, Horowitz, Netanel A., Kaplan, Marielle, Halberthal, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8537975/
https://www.ncbi.nlm.nih.gov/pubmed/34702617
http://dx.doi.org/10.1016/j.vaccine.2021.10.016

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8537975/
https://www.ncbi.nlm.nih.gov/pubmed/34702617
http://dx.doi.org/10.1016/j.vaccine.2021.10.016

Ejemplares similares